Chimeric Antigen Receptor News and Research

RSS

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

A team of researchers assessed the immune response after administering a SARS-COV-2 vaccine in immuno-compromised subjects who are potentially at an increased risk to experience severe COVID-19 and inadequate response to SARS-CoV2 vaccination.

17 Jan 2022

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy- also pioneered at Penn- for solid cancer tumors and offers a promising new strategy in the fight against cancer.

11 Jan 2022

New grant program launches to advance therapeutic discovery for follicular lymphoma

Today saw the launch of a dedicated grant program aimed at advancing therapeutic discovery for follicular lymphoma (FL), The Follicular Lymphoma Foundation (FLF) CURE FL Awards - Curative Research to Eliminate Follicular Lymphoma.

10 Jan 2022

In vivo generation of engineered CAR T cells can reduce fibrosis and restore cardiac function after heart injury

A novel immunotherapy strategy using in vivo generation of transient engineered chimeric antigen receptor (CAR) T cells, through the delivery of modified mRNA, can reduce fibrosis and restore cardiac function in a mouse model of heart failure, researchers report.

6 Jan 2022

New approach with mRNA preparation reprograms T cells to attack heart fibroblasts

An experimental immunotherapy can temporarily reprogram patients' immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

6 Jan 2022

Study may lead to a paradigm shift in the care for adults who relapse from large B-cell lymphoma

A study published this month in the New England Journal of Medicine (NEJM) may change the standard of care for adults who relapse from large B-cell lymphoma.

17 Dec 2021

Lymphoma patients can benefit from early CAR T treatment, study shows

Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers.

13 Dec 2021

Study offers new hope for large B-cell lymphoma patients

Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, higher-intensity chemotherapy, followed by a stem cell transplant.

13 Dec 2021

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

12 Dec 2021

Potentially serious side effect reported after CAR-T cell therapy for multiple myeloma

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma.

11 Dec 2021

Penn researchers illuminate key molecular details of T-cell exhaustion process

Specially engineered immune cells called CAR T cells have proven themselves to be a powerful weapon against blood cancers, but against solid tumors they are much less effective, due in part to a process called T-cell exhaustion.

2 Dec 2021

DNA sequencing of residual disease accurately identifies leukemia patients who would relapse

In pediatric and young adult patients with acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel (Kymriah), DNA sequencing-based detection of residual disease between three and 12 months accurately identified all patients who would eventually relapse, while other methods were less predictive.

1 Dec 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021

CAR-T cell treatment's efficacy in hematological malignancies predicted by epigenetics

One in five cancers affects blood cells and lymph nodes, causing leukemias and lymphomas, respectively. Although their treatment with drugs has led to a great advance in their cure, there are cases where there is no clinical response or resistance to them is generated.

21 Oct 2021

New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

A retrospective study led by Northwestern Medicine investigators found that the chimeric antigen receptor (CAR) T-cell immunotherapy drug tisagenlecleucel demonstrated safety and efficacy in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-cell ALL), even when the drug doesn't meet the FDA's strict manufacturing standards.

19 Oct 2021

Newly developed gel helps improve the effectiveness of immunotherapy in glioblastoma

Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.

7 Oct 2021

CAR-T cells require an abundance of antigens to efficiently kill solid tumors

Immunotherapy, which harnesses the power of the body's immune system to fight disease, is gaining huge traction in treating cancer.

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Researchers recently investigated the effect of infection with SARS-CoV-2 in patients with hematologic malignancies in minority populations.

21 Sep 2021